Celiac Disease Beyond the Gluten-Free Diet: Refractory Celiac and Complications Doctors Watch For

Research-informed explainer — last updated April 12, 2026

For most people, a strict gluten-free diet reverses the intestinal damage caused by celiac disease — but roughly 1 in 5 patients continues to have symptoms or persistent villous atrophy despite rigorous dietary adherence, and a smaller subset develops true refractory celiac disease, a serious condition requiring specialist management. Understanding why some patients don't respond — and what complications gastroenterologists monitor for — is essential for anyone who feels like the gluten-free diet isn't doing enough.

This article draws on research from five gastroenterologists. Carol Semrad, MD, Chairperson of the Nutrition Advisory Committee at University of Chicago Medicine, contributed landmark work on the 2022 ACG celiac guidelines update (375 citations), the discovery that reovirus infection can trigger immune responses to dietary antigens (449 citations), NK-cell reprogramming in refractory celiac (305 citations), and how chronic inflammation permanently reshapes intestinal immunity (191 citations). Stavros Stavropoulos, MD, of Mount Sinai South Nassau, published a national survey of adult celiac characteristics in the U.S. (536 citations). Michael Camilleri, MD, at Mayo Clinic, has authored foundational work on intestinal barrier function and leaky gut mechanisms (993 and 858 citations, respectively). Lucinda Harris, MD, Professor at Mayo Clinic Arizona, led a randomized trial of larazotide acetate as a pharmacologic adjunct to the gluten-free diet (187 citations). Bruce Greenwald, MD, at the University of Maryland Medical Center, has published on gliadin's direct effects on intestinal permeability in celiac patients (211 citations).

What happens in the intestine when someone with celiac eats gluten

In celiac disease, ingested gluten peptides trigger an autoimmune response that destroys the villi — the small finger-like projections lining the small intestine responsible for absorbing nutrients. The result is villous atrophy, which causes malabsorption of iron, calcium, folate, and fat-soluble vitamins even before a person notices GI symptoms.

The mechanism is more layered than once thought. Research published in Science by Semrad and colleagues showed that prior infection with reovirus — an otherwise harmless common pathogen — can break immune tolerance to dietary antigens, potentially explaining why some genetically susceptible individuals develop celiac disease after what seemed like an ordinary illness. Separately, Camilleri's work in Gut describes how compromised intestinal barrier function allows gluten peptides to reach immune cells in the lamina propria more readily, amplifying the inflammatory cascade.

Why some patients don't improve on a gluten-free diet

A national survey by Stavropoulos found that the majority of U.S. adults with celiac report incomplete symptom resolution, even among those following the diet carefully. There are several explanations:

Inadvertent gluten exposure is the most common reason. Hidden gluten in medications, communion wafers, cross-contaminated oats, and shared kitchen surfaces accounts for many apparent non-responders. The ACG 2022 guidelines emphasize that even trace amounts — below the 20 ppm threshold on most food labels — can perpetuate intestinal injury in sensitive individuals.

Overlapping conditions such as irritable bowel syndrome, small intestinal bacterial overgrowth (SIBO), lactose intolerance, and microscopic colitis frequently coexist with celiac disease and cause symptoms even when villous architecture has normalized.

Persistent intestinal permeability is a third mechanism. Greenwald's work in Nutrients demonstrated that gliadin directly increases permeability in intestinal biopsy explants from celiac patients — an effect that may outlast strict dietary avoidance in some individuals. Camilleri's review in Neurogastroenterology & Motility explains how disrupted tight junction proteins contribute to ongoing immune activation even with minimal gluten exposure.

Refractory celiac disease (RCD) is diagnosed when villous atrophy persists after 12 months on a strict gluten-free diet with no identifiable cause. RCD affects approximately 1–2% of celiac patients. RCD type I involves abnormal intraepithelial lymphocytes with a normal immunophenotype; RCD type II involves clonal, phenotypically aberrant intraepithelial lymphocytes and carries a significantly elevated risk of enteropathy-associated T-cell lymphoma (EATL), a rare but aggressive malignancy. Research on NK-cell reprogramming by Semrad and colleagues in The Journal of Experimental Medicine showed that cytotoxic T lymphocytes in RCD take on properties of natural killer cells, contributing to the tissue destruction that drives malignant transformation.

Complications specialists monitor for

The 2022 ACG guidelines update recommends that patients with persistent symptoms or confirmed RCD undergo regular monitoring for:

• Enteropathy-associated T-cell lymphoma: Patients with RCD type II have a 5-year survival rate of approximately 50% once EATL develops, making early detection critical.
• Nutritional deficiencies: Iron, B12, folate, vitamin D, zinc, and copper deficiencies are common even years into a gluten-free diet.
• Osteoporosis: Unrecognized malabsorption of calcium and vitamin D before diagnosis leads to reduced bone mineral density in the majority of adult celiac patients.
• Small bowel adenocarcinoma: Celiac disease is associated with a two- to threefold increased risk of small bowel cancer compared to the general population.

Emerging pharmacologic approaches

Because strict dietary avoidance is difficult and incomplete in practice, researchers have pursued drug therapies to adjunct or eventually replace the gluten-free diet. Larazotide acetate, a tight junction regulator, was evaluated in a randomized, double-blind trial led by Harris and colleagues. The study found that lower doses of larazotide appeared to prevent the increase in gastrointestinal symptom severity induced by deliberate gluten challenge, though effects on intestinal permeability were variable. An enzyme-based approach — latiglutenase, designed to degrade gluten peptides before they can trigger an immune response — was tested in a trial that Semrad contributed to; the 2016 study in Gastroenterology found no significant difference from placebo in reducing villous atrophy or improving symptoms across the full study population, though subgroup analyses suggested possible benefit in a subset of patients.

Research published in Cell by Semrad's group demonstrated that chronic inflammation permanently reshapes tissue-resident immunity in celiac disease, with immune memory that persists in the intestinal mucosa long after gluten exposure stops. This finding helps explain why recovery is slow and why some patients may never fully normalize their intestinal architecture despite dietary compliance.

Questions to ask your doctor

• My symptoms haven't improved after 12 months on a strict gluten-free diet — should I be evaluated for refractory celiac disease?
• What blood tests and follow-up biopsies do you recommend to confirm mucosal healing?
• Do I need a DEXA scan to assess bone mineral density given my celiac history?
• Could I have a coexisting condition — like SIBO, IBS, or microscopic colitis — contributing to my ongoing symptoms?
• Are there clinical trials for celiac treatments I might qualify for?
• How should I handle cross-contamination risk in my specific living situation?

The bottom line

A gluten-free diet remains the cornerstone of celiac treatment, but it is not sufficient for every patient. Anyone with persistent symptoms or documented villous atrophy after a year of careful adherence deserves a systematic evaluation for inadvertent gluten exposure, coexisting conditions, and — in a minority of cases — true refractory celiac disease. Specialist gastroenterologists trained in celiac disease can distinguish these scenarios and coordinate appropriate surveillance and emerging therapies.